OMAHA, Neb.--(BUSINESS WIRE)--Transgenomic, Inc. (NASDAQ:TBIO), today announced that it has signed an amended license agreement with Exiqon A/S for the expansion of rights to their proprietary Locked Nucleic Acid (LNA™) oligonucleotides, which offer dramatically improved sensitivity and specificity compared to traditional DNA chemistries. The amended agreement provides Transgenomic with access to LNA oligos for use with all of the company’s proprietary ultra-high sensitivity mutation enrichment technologies, including its Multiplexed ICE COLD-PCRTM (MX-ICP). It covers Transgenomic’s commercial worldwide use of LNA oligos for analysis of all cancer genes on all platforms, including cutting edge approaches such as next-generation sequencing (NGS).
“This expanded agreement supports the global commercialization of our revolutionary Multiplexed ICE COLD-PCR enrichment technology,” noted Paul Kinnon, President and Chief Executive Officer of Transgenomic. “Use of Exiqon’s LNA oligos with our MX-ICP technology significantly enhances identification of very low concentration cancer mutations in liquid biopsies. This is vital to enabling clinicians to initially choose the right mutation-targeted cancer therapy and also enables them to monitor the cancer and detect emerging resistance to drugs over the course of treatment.”
Mr. Kinnon continued, “Use of LNAs enables MX-ICP to work equally well in all tumor DNA analyses, whether in tissue biopsies or in blood- or urine-based liquid biopsies. The expanded agreement guarantees our access to LNA oligos for all of our ultra-high mutation enrichment technologies, including the multiplexed MX-ICP that makes possible simultaneous analysis of multiple mutations in multiple genes. It covers Transgenomic’s commercial use of LNA oligos worldwide for cancer genes on any platform and for all applications. This is pivotal as we build a global franchise for this powerful genetic analysis technique that has the potential to make precision medicine an everyday reality.”
Transgenomic’s Multiplexed ICE COLD-PCR offers major advantages for users of current sequencing technologies. It delivers at least a 100-fold improvement in sensitivity compared to standard methodologies and enriches both known and previously unknown genetic alterations in any gene using a single multiplexed assay. The ultra-high sensitivity of MX-ICP makes it feasible to conduct comprehensive genomic analyses using either tissue or liquid biopsies. MX-ICP is both platform agnostic and compatible with all sequencing platforms found in labs today, including the newest ultra-high throughput NGS instruments. MX-ICP is robust, easy to use and easily implemented, requiring minimal disruption to established sequencing workflows.
“This expanded agreement with Transgenomic highlights the outstanding sensitivity and specificity, as well as the versatility of our LNA technology,” noted Lars Kongsbak, Chief Executive Officer of Exiqon. “We welcome the opportunity to collaborate with technology innovators such as Transgenomic to bring the benefits of our unique chemistries to a variety of important applications.”
For more information about Multiplexed ICE COLD-PCR technology, visit www.transgenomic.com/pharma-services/technology/ice-cold-pcr.
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM and its unique genetic tests provided through its Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.